Patent ID: 9726662
Date: 2017-08-08
CPC Classifications: A61P,C12N,C12Q,G01N

Claim:
1. An in vitro screening method to identify a candidate drug substance capable of ameliorating hypertrophic cardiomyopathy, comprising: (i) providing a cardiomyocyte, the cardiomyocyte having been obtained by differentiating a multipotent or pluripotent stem cell in vitro; (ii) inducing a cardiac hypertrophic phenotype in said cardiomyocyte, wherein the cardiac hypertrophic phenotype is selected from the group consisting of: increased cell size, increased protein synthesis, increased sarcomeric organization, activation of gene expression patterns characteristic of cardiomyopathic cells, and activation of ANF and/or BNP expression; (iii) contacting the cardiomyocyte displaying the cardiac hypertrophic phenotype with a drug substance; and (iv) determining a responsive change in the cardiac hypertrophic phenotype of the cardiomyocyte; wherein the responsive change is a decrease in or loss of the cardiac hypertrophic phenotype and said decrease or loss identifies the drug substance as a candidate drug capable of ameliorating hypertrophic cardiomyopathy.